On September 15, Boston Scientific fell 3.04% in regular trading, trading at $43.71 per share, with turnover of $205 million. The decline came as two major investment banks successively lowered their price targets on the stock, reflecting persistent market anxiety over the aftermath of the company's cybersecurity incident.

Bernstein cut its target price on Boston Scientific significantly from $72 to $60 while maintaining an Outperform rating. Earlier, Citigroup also reduced its target from $61 to $57, keeping a Buy rating. According to FactSet, the stock's mean analyst target price now stands at $61.11. The consecutive downgrades underscore growing concerns about the operational and financial fallout from the cybersecurity incident first identified on August 25, which caused a global network outage affecting order processing and product shipments.

The company has acknowledged in SEC filings that it is unlikely to meet its third-quarter and full-year net sales growth and adjusted EPS guidance ranges. While Boston Scientific has noted that its sterilization facilities are fully operational and manufacturing has resumed across most global sites, management is reassessing its strategic framework, with updated forward guidance expected at its October earnings call. The company has also stated it does not expect the incident to materially impact its long-term financial position.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)